

Surgical strategy for atrial functional mitral regurgitation with atrial fibrillation

Chunrong Bao,MD1,Ke Wei,MD1, Dongfang Zhao,MD2,Junwen Zhang, MD1, Ju Mei,
MD1, Nan Ma, MD1

1. Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine,
Shanghai Jiaotong University, China

2. NSW Health Pathology, Sydney, NSW, Australia

Chunrong Bao and Ke Wei are co-first authors.

Correspondence to:

Ju Mei, Professor

Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai
Jiaotong University

1665, Kongjiang Road, Yangpu District, Shanghai, 200092

Tel: +86 13801669185

Email: mei_ju63@126.com

Nan Ma, Professor

Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai
Jiaotong University

1665, Kongjiang Road, Yangpu District, Shanghai, 200092

Tel: +86 15001994818

Email: manancts@sina.com

Running head : Surgical strategy for AFMR with AF

Disclosures: The authors have declared that no conflict of interest exists.

Funding: The work was sponsored by National Natural Science Foundation of China (grant number: 82170313)

1 **Abstract**

2 Background

3 With the growing prevalence of atrial fibrillation (AF), atrial functional mitral
4 regurgitation (AFMR) combined with AF is expected to become a common clinical issue. We
5 have summarized various surgical treatment strategies based on the degree of mitral
6 regurgitation (MR) alongside rhythm control therapy for patients with AFMR and AF.

7 Methods

8 This retrospective study included 145 patients with AF and MR from January 2017 to
9 January 2023. 33 patients with AF and moderate AFMR were designated as the moderate
10 atrial regurgitation (MAR) group. 56 patients with AF and severe AFMR were designated as
11 the severe atrial regurgitation (SAR) group. The remaining 56 patients with AF and severe
12 primary MR were designated as the severe primary regurgitation (SPR) group. All patients in
13 the MAR group underwent thoracoscopic AF procedure via a unilateral approach. Patients in
14 the SAR and SPR groups underwent mitral valvuloplasty plus the Cox Maze IV procedure
15 (CMP IV). Descriptive characteristics and outcomes were analysed.

16 Results

17 Twenty-three patients maintained sinus rhythm (SR) following thoracoscopic AF
18 procedure in the MAR group at average 2.6 ± 1.1 years follow-up. The degree of regurgitation
19 improved in 26 patients, remained unchanged in 6 patients, and worsened in 1 patient. SR
20 maintenance benefits MR reduction ($P < 0.0001$) compared to the non-SR patients. There was
21 no significant difference in the rate of SR maintenance following mitral valvuloplasty plus
22 CMP IV between SAR (43 patients, 79.6%) and SPR (49 patients, 87.5%) groups. At the last
23 follow-up, echocardiography in the SAR group showed 47 cases with no mitral regurgitation,

24 4 cases with mild regurgitation, and 1 case with moderate regurgitation. The left atrial
25 diameter in the SAR group remained larger than in the SPR group ($P<0.001$).

26 Conclusions

27 Rhythm control therapy is the cornerstone treatment for AFMR patients with AF.
28 Thoracoscopic AF procedure is effective and minimally invasive for moderate AFMR
29 patients with AF. For severe AFMR patients with AF, we recommend CMP IV plus mitral
30 valvuloplasty for safety and effectiveness.

31 Keywords: atrial functional mitral regurgitation; atrial fibrillation; thoracoscopic
32 ablation; Cox-Maze IV procedure;

33

34

35

36

37

38

39

40

41

42

43

44

45 **Introduction**

46 Atrial functional mitral regurgitation (AFMR) is receiving increasing attention as a type
47 of functional mitral regurgitation (MR) secondary to structural or functional abnormalities of
48 the left atrium ¹. Clinically, it is more common in patients with non-paroxysmal atrial
49 fibrillation (AF) ^{2,3}. Epidemiological studies have shown that the incidence of moderate to
50 severe AFMR in patients with persistent AF is 4-8%, rising to 28% in those with AF lasting
51 more than 10 years ^{4,5}. With the growing prevalence of AF, AFMR combined with AF is
52 expected to become a common clinical issue. However, there is still a lack of research
53 (particularly surgical studies) addressing this combination. ^{6,7}. Utilising a single treatment
54 modality for MR with functional regurgitation is often unsatisfactory. Results from catheter
55 ablation studies suggest that restoring sinus rhythm (SR) can reduce valve regurgitation
56 through cardiac remodelling. However, the success rate of catheter ablation and the certainty
57 of cardiac remodelling in reducing regurgitation remain concerning. We have summarized
58 data from AFMR patients with AF treated at our centre, employing different treatment
59 strategies based on the degree of MR alongside rhythm control therapy.

60 **Methods**

61 *Patient Selection & Characteristics*

62 This retrospective cohort study included 145 patients with AF and MR treated at the
63 Department of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong
64 University School of Medicine, from January 2017 to January 2023. Thirty-three patients
65 with AF and moderate AFMR were designated as the moderate atrial regurgitation (MAR)
66 group. 56 patients with AF and severe AFMR were designated as the severe atrial
67 regurgitation (SAR) group. The remaining 56 patients with AF and severe primary MR were
68 designated as the severe primary regurgitation (SPR) group. All patients received appropriate

69 rate control, anti-hypertensives, and diuretic therapy before preoperative cardiac echo
70 examination. The diagnostic criteria for AFMR are based on relevant literature: exclusion of
71 organic mitral valve disease, left ventricular ejection fraction (LVEF) $\geq 50\%$, no abnormal left
72 ventricular wall systolic activity, and left ventricular end-diastolic diameter < 55 mm^{8,9}. The
73 degree of mitral regurgitation was diagnosed according to guidelines and confirmed by two
74 physicians.

75 The MAR group included 20 males and 13 females, with an average age of 70.27 ± 6.46
76 years. Four cases had persistent AF and 29 had long-term persistent AF. The history of AF
77 averaged 7.12 ± 4.83 years, and the median CHA2DS2-VASc score was 3 points (0-6).
78 Preoperative echocardiography showed moderate MR in 33 cases. The left atrium diameter
79 was 48.15 ± 4.19 mm, the left ventricular end-diastolic diameter was 49.91 ± 3.29 mm, and
80 LVEF was $56.39 \pm 4.90\%$. Preoperative cardiac function was NYHA grade I in 1 case, grade II
81 in 17 cases, grade III in 12 cases, and grade IV in 3 cases. There were 22 patients with
82 tricuspid regurgitation, 8 with coronary heart disease, 19 with hypertension, 10 with diabetes,
83 and 3 with a history of stroke. Three patients had undergone catheter ablation. Baseline
84 characteristics of MAR group are described in Table 1.

85 In the SAR group, there were 37 males and 19 females, with an average age of
86 70.54 ± 5.91 years. All patients had long-term persistent AF with a history of 6.10 ± 4.32 years.
87 The median CHA2DS2-VASc score was 3 points (3-4). Thirty-eight patients had moderate
88 or above tricuspid regurgitation, 15 had coronary heart disease, 42 had hypertension, 15 had
89 diabetes, and 7 had a history of stroke. Four patients had a history of catheter ablation.

90 In the SPR group, there were 36 males and 20 females, with an average age of
91 66.43 ± 6.39 years. Forty-four patients had long-term persistent AF, and 12 had persistent AF,
92 with an AF history of 4.44 ± 2.58 years. The median CHA2DS2-VASc score was 2 points (2-

93 3). There were 23 patients with moderate or above tricuspid regurgitation, 6 with coronary
94 heart disease, 27 with hypertension, 9 with diabetes, and 4 with a history of stroke. One
95 patient had a history of catheter ablation. Baseline characteristics of both groups are
96 described in Table 1.

97 *Surgical Procedures*

98 All patients in the MAR group underwent thoracoscopic AF procedure via a unilateral
99 approach as previously described [5, 6]. After anesthesia, patients were positioned in the right
100 lateral decubitus position. Chest wall incisions were made at the 6th, 7th, 8th, or 6th, 8th, and
101 8th intercostal spaces near the inferior angle of the left scapula. The ablation routes included
102 ablation of the left and right pulmonary veins, the posterior wall of the left atrium, the
103 ablation line from the left pulmonary vein to the anterior mitral annulus (Dallas lesion), the
104 ablation line from the left pulmonary vein to the resection edge of the left atrial appendage,
105 and the ablation line between the two inferior pulmonary veins. The left atrial appendage was
106 either resected with a stapler or clamped with an atrial appendage clip. Marshall's ligament
107 and epicardial autonomic ganglia were ablated by ablation pen. If AF could not be terminated
108 after all steps, cardioversion was performed.

109 Patients in the SAR and SPR groups underwent mitral valvuloplasty plus the Cox Maze
110 IV procedure (CMP IV). These procedures were performed under general anesthesia and
111 extracorporeal circulation. A minimally invasive approach was used to establish
112 extracorporeal circulation through the femoral artery and vein, with a small incision made in
113 the fourth intercostal space on the right chest wall. All mitral annuloplasties were performed
114 with a prosthetic ring. Additional techniques included artificial chordae, partial excision of
115 the posterior leaflets, junctional suturing, and edge-to-edge suturing. If mitral annuloplasty
116 failed, mitral valve replacement was performed. CMP IV included standard ablation routes

117 for both the left and right atria, completed with a bipolar clamp, with isthmus ablation
118 supplemented by cryoenergy. The left atrial appendage was resected or sutured in a double-
119 layered linear fashion. Concomitant procedures included tricuspid valvuloplasty, coronary
120 artery bypass grafting.

121 *Postoperative Care and Follow-up*

122 Postoperatively, all patients received anticoagulation therapy with warfarin. If patient's
123 heart rate exceeded 70 beats/min, oral amiodarone would be administered for 3 months.
124 Patients unable to maintain SR were treated with rate control. Recurrent AF was managed
125 with cardioversion under adequate anticoagulation. Follow-up was conducted through
126 outpatient visits and telephone calls, including symptom evaluation and 24-hour dynamic
127 electrocardiograms at 3, 6, and 12 months, and every 6 months thereafter. Any documented
128 atrial tachyarrhythmia episodes lasting 30 seconds or longer were considered a recurrence
129 after a 3-month blanking period. Postoperative mitral valve function was assessed by
130 echocardiography at 3, 6, and 12 months, and at least annually thereafter.

131 *Statistical Analysis*

132 Statistical analysis was performed using R (version 4.3.2). Measurements are expressed
133 as mean \pm standard deviation and compared using the t-test. Count data are expressed as rates
134 (percentages) and compared using Fisher's exact test. Kaplan-Meier (KM) curve was utilized
135 to analyze the success rates of AF treatments, while differences in success rates across groups
136 were assessed using the log-rank test, with a P-value of less than 0.05 considered statistically
137 significant. Left atrial diameter values over time are shown in box plots, with median,
138 quartiles, and outliers. Differences were tested using repeated measures ANOVA. Changes
139 in MR severity are displayed in stacked bar charts, indicating patient counts and percentages.

140 Differences across stages were analyzed using Chi-square tests, with statistical significance
141 set at $P < 0.05$. Factors associated with recurrence following AF ablation were identified
142 through an extensive review of the literature and previous experiences, and included in a
143 multivariate regression model following univariate analysis where a P-value less than 0.1 was
144 significant. A multivariate Cox proportional hazards regression model was employed to
145 evaluate risk factors for AF recurrence, providing a comprehensive analysis of potential
146 predictors.

147 *Ethical review*

148 This study has been approved by the Medical Ethics Committee of Xinhua Hospital
149 Affiliated to Shanghai Jiaotong University School of Medicine, and informed consent was
150 obtained from all participants.

151 **Results**

152 *Clinical Outcomes of AF Combined with Moderate AFMR*

153 Thoracoscopic AF procedure via a unilateral approach was successfully performed in all
154 patients in the MAR group. There was no conversion to thoracotomy and no perioperative
155 mortality. No blood products were transfused, and no serious postoperative complications
156 occurred. SR was maintained in 30 patients (90.9%) at discharge. Echocardiography before
157 discharge showed no mitral regurgitation in 18 cases, mild mitral regurgitation in 10 cases,
158 and moderate mitral regurgitation in 4 cases. The left atrium diameter (47.06 ± 3.99 mm), left
159 ventricular end-diastolic diameter (49.58 ± 3.16 mm), and LVEF ($55.73 \pm 5.40\%$) were not
160 statistically different from pre-procedure measurements.

161 The last follow-up was in June 2023, with follow-up durations ranging from 1 to 6 years
162 (average: 2.6 ± 1.1 years). Twenty-three patients (69.70%) maintained SR, confirmed by 24-
163 hour electrocardiography. The Kaplan-Meier curve illustrating freedom from AF recurrence
164 is shown in Figure 1A. At the last follow-up, 17 patients had no mitral regurgitation, 9 had
165 mild mitral regurgitation, 6 had moderate mitral regurgitation, and 1 had severe mitral
166 regurgitation. The degree of regurgitation improved in 26 patients compared to pre-surgery
167 levels, remained unchanged in 6 patients, and worsened in 1 patient. The left atrium diameter
168 (46.42 ± 4.40 mm), left ventricular end-diastolic diameter (49.94 ± 3.32 mm), and LVEF
169 ($58.64\pm 3.88\%$) were not statistically different from pre-procedure measurements.

170 *Effects of Rhythm Control on Cardiac Remodeling and Mitral Regurgitation in the MAR*
171 *Group*

172 Patients in the MAR group were divided into two cohorts based on their ability to
173 maintain SR post-surgery. SR maintenance benefits MR reduction ($P<0.0001$) compared to
174 the non-SR patients (Figure 1B). The left atrial diameters of the SR and non-SR patients were
175 47.26 ± 4.06 mm vs. 50.20 ± 3.94 mm before surgery ($P=0.063$) and 46.48 ± 4.00 mm vs.
176 48.40 ± 3.84 mm at discharge ($P=0.209$), showing no statistical difference between the groups.
177 At the last follow-up, the left atrial diameter was 45.04 ± 3.48 mm in the SR patients vs.
178 49.60 ± 4.81 mm in the non-SR patients ($P=0.004$), a statistically significant difference (Figure
179 2A). The Corresponding changes in MR degree in SR and non-SR patients is shown in Figure
180 2B.

181 *Clinical Outcomes of AF Combined with Severe AFMR*

182 All 56 patients in the SAR group completed the valve procedure, CMP IV, and other
183 concomitant procedures. Two patients died within 30 days post-surgery due to postoperative

184 ARDS and pulmonary infection. Postoperative complications included bleeding, low cardiac
185 output, pulmonary infection, and acute kidney injury. Three cases (5%) required
186 postoperative electrical cardioversion therapy. At discharge, 50 patients (92.6%) were in SR;
187 50 cases had no mitral regurgitation and 2 had mild mitral regurgitation. The left atrium
188 diameter was 48.31 ± 2.60 mm, significantly smaller than pre-surgery ($P < 0.001$), while the left
189 ventricular end-diastolic diameter (49.41 ± 2.93 mm, $P = 0.056$) and LVEF ($54.87 \pm 5.46\%$,
190 $P = 0.385$) showed no significant changes from pre-surgery.

191 The mean follow-up period was 2.6 ± 1.1 years. At the last follow-up, 43 patients (79.6%)
192 in the SAR group maintained SR (KM curve shown in the Figure 3). Echocardiography
193 showed no mitral regurgitation in 47 cases, mild regurgitation in 4 cases, and moderate
194 regurgitation in 1 case. The left atrium diameter was 48.46 ± 3.80 mm, significantly smaller
195 than pre-surgery ($P < 0.001$), while the left ventricular end-diastolic diameter (51.52 ± 3.54 mm,
196 $P = 0.225$) and LVEF ($54.80 \pm 4.93\%$, $P = 0.310$) showed no significant differences from pre-
197 surgery measurements.

198 *Comparison of Perioperative Data between SAR and SPR Groups*

199 The SAR group patients were significantly older and had longer AF durations and more
200 preoperative comorbidities than the SPR group. Detailed information is presented in Table 1.
201 In the SAR group, 53 patients underwent mitral valvuloplasty with rings of varying sizes,
202 including 11 patients with No. 28 ring, 24 patients with No. 30 ring, 16 patients with No. 32
203 ring, and 2 patients with No. 34 ring. Three patients underwent mitral valve replacement with
204 bioprosthetic valves. Concomitant procedures included tricuspid valvuloplasty (35 cases),
205 coronary artery bypass grafting (8 cases), and left ventricular outflow tract obstruction (2
206 cases). In the SPR group, 50 patients underwent mitral valvuloplasty with rings of varying
207 sizes, including 10 patients with No. 28 ring, 23 patients with No. 30 ring, 15 patients with

208 No. 32 ring, and 2 patients with No. 34 ring. Six patients underwent mitral valve replacement
209 (3 bioprosthetic and 3 mechanical valves). Concomitant procedures included tricuspid
210 valvuloplasty (19 cases) and coronary artery bypass grafting (2 cases). All patients in both
211 groups completed CMP IV. There was no perioperative mortality in the SPR group. The SAR
212 group had a slightly higher incidence of postoperative complications (Table 2). Fifty patients
213 (92.6%) in the SAR group and 51 patients (91.1%) in the SPR group were in SR at discharge,
214 with no significant difference between the groups ($P=0.368$). At the last follow-up, 43
215 patients (79.6%) in the SAR group and 49 patients (87.5%) in the SPR group maintained SR.
216 The KM curves for the SR maintenance rate showed no statistical difference between the
217 groups (Figure 3A).

218 *Comparison of Mitral Regurgitation and Cardiac Remodeling Between SAR and SPR* 219 *Groups*

220 Preoperative echocardiography revealed that in the SAR group, 53 cases were
221 Carpentier type I and 3 were type IIIb MR. In the SPR group, there were 5 cases of
222 Carpentier type I and 51 cases of type II MR. There was no significant difference in left atrial
223 diameter between the groups ($P=0.532$). The SPR group had a significantly larger left
224 ventricular diameter ($P<0.001$) and lower ejection fraction ($P<0.001$) compared to the SAR
225 group. Before discharge, 50 cases in the SAR group had no mitral regurgitation, and 2 had
226 mild regurgitation. In the SPR group, 45 cases had no mitral regurgitation, 4 had mild
227 regurgitation, and 1 had moderate regurgitation. The left atrial diameter in the SAR group
228 was larger than in the SPR group ($P<0.001$). The ejection fraction in the SAR group was
229 lower than in the SPR group, with no significant difference in left ventricular diameter
230 ($P=0.077$). At the last follow-up, echocardiography showed that in the SAR group, 47 cases
231 had no mitral regurgitation, 4 had mild regurgitation, and 1 had moderate regurgitation. In the

232 SPR group, 42 cases had no mitral regurgitation, 6 had mild regurgitation, 1 had moderate
233 regurgitation, and 1 had severe regurgitation. The left atrial diameter in the SAR group
234 remained larger than in the SPR group ($P<0.001$), with no significant difference in left
235 ventricular diameter ($P=0.263$) and ejection fraction ($P=0.001$). Detailed data are presented in
236 Table 3. The changes in MR degree in the SAR and SPR groups are shown in Figure 3B and
237 3C.

238 *Analysis of Risk Factors for Recurrence of AF*

239 Cox multivariate analysis indicated that AF recurrence in the MAR group was
240 associated with a lack of regurgitation reduction (HR 0.0369; 95% CI 0.0026-0.5156;
241 $P=0.0142$), reduction of left atrial diameter (HR 0.01865; 95% CI 0.0007-0.5016; $P=0.0177$),
242 and was independent of age, CHA2DS2–VASc score, preoperative or postoperative left atrial
243 diameter. In severe MR, the risk factors for AF recurrence in the SAR group included
244 postoperative left atrial diameter greater than 50 mm (HR 4.081; 95% CI 1.109-15.016;
245 $P=0.0344$), with no association with age, AF duration, CHA2DS2–VASc score, preoperative
246 left atrial diameter, or residual mitral regurgitation. In the SPR group, AF recurrence was
247 associated with a postoperative left atrial diameter greater than 50 mm (HR 12.480; 95% CI
248 1.288-120.898; $P=0.0294$) and residual mitral regurgitation (HR 16.358; 95% CI 1.604-
249 166.850; $P=0.0183$), with no relation to age, AF duration, CHA2DS2–VASc score, or
250 preoperative left atrial diameter. This study did not identify risk factors for the recurrence of
251 mitral regurgitation in either group.

252 **Discussion**

253 AF and MR are progressive conditions that exacerbate each other, leading to more
254 severe symptoms, rapid disease progression, and serious consequences such as heart failure

255 ¹⁰. Timely and effective treatment is particularly important when AF is combined with MR ¹¹.
256 We selected different treatment strategies based primarily on the degree of mitral
257 regurgitation, which were all predicated on the treatment of AF. Our data suggests that for
258 moderate AFMR combined with AF, rhythm control via thoracoscopic AF procedure yields
259 satisfactory results. Maintenance of SR improves cardiac remodeling and reduces mitral
260 regurgitation.

261 For severe AFMR combined with AF, we employed a combination of rhythm control
262 and valvular intervention using the classic CMP IV surgical technique in conjunction with
263 mitral valvuloplasty. This approach aligns with standard surgical guidelines for treating AF
264 combined with severe MR. However, most previous evidence pertains to primary mitral
265 regurgitation combined with AF, not AFMR combined with AF ^{12,13}. Our study demonstrates
266 that the safety and efficacy of CMP IV combined with mitral valvuloplasty for severe AFMR
267 with AF are comparable to the outcomes in primary mitral regurgitation with AF. AF is the
268 initiating factor of AFMR, making it the primary target for treatment. In cases of functional
269 mitral regurgitation, merely treating the regurgitation without addressing the primary disease
270 often fails to yield favourable outcomes ¹⁴. In cases of moderate regurgitation, the structural
271 changes in the atrium and mitral valve are reversible ^{15,16}. Although rhythm control may
272 reduce or eliminate mitral regurgitation through cardiac remodeling, the efficiency remains
273 unsatisfactory ^{17,18}. The effectiveness of rhythm control is crucial in the management of AF.
274 However, a large proportion of patients with AFMR have long-standing persistent AF,
275 significant left atrium enlargement, high CHA2DS2–VASc scores, and other factors that
276 impede successful treatment or maintenance of SR ¹⁹. Previous research has shown that
277 thoracoscopic surgery may be more effective than catheter ablation in SR maintenance ²⁰.
278 The thoracoscopic technique provides high-quality pulmonary vein ablation, directly ablates
279 the Marshall Ligament and autonomic ganglia from the epicardium, and enables left atrial

280 appendage excision. Our modified procedure includes the isolation of the left atrial posterior
281 wall to further improve success rates²¹. Our data shows favourable results for AF patients
282 with moderate AFMR, although subsequent catheter ablation may be required for patients
283 with unsuccessful outcomes. This approach is reasonable for AFMR patients who require a
284 more robust method to maintain SR and interrupt the cycle of AF, MR, and heart failure²².

285 Patients with severe AFMR are more challenging to manage for clinicians. We therefore
286 utilized CMP-IV, a classic surgical technique for treating AF, which has the highest single
287 success rate in clinical practice. Despite their increased age, complexity, and potential
288 complications, patients with severe AFMR still require treatment options that offer a high
289 degree success in maintaining SR. As such, these patients would benefit the most from
290 individualized ablation strategies or further minimally invasive procedures.

291 AFMR is mitral regurgitation secondary to structural or functional abnormalities of the
292 left atrium, leading to mitral annulus enlargement and an imbalance between annulus and
293 leaflet area. Although functional in nature, AFMR may still involve abnormal mitral valvular
294 structure^{23,24}. Studies suggest that there is potential for mitral valve with structural
295 abnormalities to recover with improved cardiac remodeling²⁵. However, for most patients
296 with severe AFMR, surgical valvuloplasty is a necessity due to underlying structural
297 abnormalities^{26,27}. In patients with AFMR, even with successful AF treatment, cardiac
298 remodeling alone may not achieve the necessary changes in the left atrium and mitral valve.
299 From the perspective of AF management, patients with AFMR and AF are often refractory to
300 catheter ablation, thoracoscopic AF procedure, and even hybrid procedures. Therefore,
301 treatment with CMP-IV should be prioritized, as it is more reasonable to undertake
302 concomitant mitral valvuloplasty with its more definitive effect, over over cardiac remodeling
303 with uncertain outcomes in MR²⁸. According to current guidelines, severe MR should be

304 treated from a valvular management perspective. Without treatment, residual mitral
305 regurgitation will self-progress and increase the inducibility of AF in the long run²⁹.

306 **Limitations**

307 While this study addresses an important topic with paucity of data on the impact of
308 therapy, it is constrained by its relatively small sample size and single-centre retrospective
309 design. The sample size was limited due to the exclusion of patients with organic mitral valve
310 disease (such as prolapse, flail leaflet, rheumatic disease, or mitral leaflet calcification) and
311 the selection of patients with normal left ventricular morphology and function to minimize
312 the interference caused by ventricular functional regurgitation. Propensity scoring matching
313 could not be applied to compare the SAR and SPR groups due to the limited sample size.
314 Patients with AFMR tend to be older, frailer, have more comorbidities, and have experienced
315 AF for a longer duration. These characteristics may not be as apparent after propensity score
316 matching.

317 **Conclusions**

318 Since AF is the primary cause of AFMR with AF, rhythm control therapy is the
319 cornerstone treatment for these patients. Thoracoscopic AF procedure is an effective and
320 minimally invasive treatment option for patients with AF and moderate AFMR. Moderate
321 AFMR can be potentially reduced by SR restoration, which promotes cardiac remodeling.
322 For patients with severe AFMR and AF, we recommend concomitant CMP-IV with mitral
323 valvuloplasty. This approach is both safe and effective, increasing the success rate of
324 achieving a resolution of both AF and MR.

325 **Acknowledgements:** We would like to thank Mr Yuanzhe Ma, Saie Shen M.D., Ms Huihua
326 Chen and Ms Yu Su for their excellent experimental and clinical support.

327

References

- 328 1. Gertz ZM, Raina A, Saghy L, et al. Evidence of atrial functional mitral regurgitation
329 due to atrial fibrillation: reversal with arrhythmia control. *Journal of the American*
330 *College of Cardiology*. 2011;58(14):1474-1481.
- 331 2. Abe Y, Takahashi Y, Shibata T. A new disease entity: Atrial functional mitral
332 regurgitation. *Journal of cardiology*. 2021;77(6):565-569.
- 333 3. Ito K, Abe Y, Takahashi Y, et al. Mechanism of atrial functional mitral regurgitation
334 in patients with atrial fibrillation: A study using three-dimensional transesophageal
335 echocardiography. *Journal of cardiology*. 2017;70(6):584-590.
- 336 4. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial
337 fibrillation. A population-based study over three decades. *The New England journal*
338 *of medicine*. 1987;317(11):669-674.
- 339 5. Amabile A, Fereydooni S, Mori M, et al. Variable definitions and treatment
340 approaches for atrial functional mitral regurgitation: A scoping review of the
341 literature. *Journal of cardiac surgery*. 2022;37(5):1182-1191.
- 342 6. Badhwar V, Alkhouli M, Mack MJ, Thourani VH, Ailawadi G. A pathoanatomic
343 approach to secondary functional mitral regurgitation: Evaluating the evidence. *The*
344 *Journal of thoracic and cardiovascular surgery*. 2019;158(1):76-81.
- 345 7. Wagner CM, Brescia AA, Watt TMF, et al. Surgical strategy and outcomes for atrial
346 functional mitral regurgitation: All functional mitral regurgitation is not the same! *The*
347 *Journal of thoracic and cardiovascular surgery*. 2024;167(2):647-655.
- 348 8. El Sabbagh A, Reddy YNV, Nishimura RA. Mitral Valve Regurgitation in the
349 Contemporary Era: Insights Into Diagnosis, Management, and Future Directions.
350 *JACC Cardiovascular imaging*. 2018;11(4):628-643.
- 351 9. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for Noninvasive
352 Evaluation of Native Valvular Regurgitation: A Report from the American Society of
353 Echocardiography Developed in Collaboration with the Society for Cardiovascular
354 Magnetic Resonance. *Journal of the American Society of Echocardiography : official*
355 *publication of the American Society of Echocardiography*. 2017;30(4):303-371.
- 356 10. Vavalle JP, Arora S. Atrial Fibrillation: Not an Innocent Bystander in the Treatment
357 of Functional Mitral Regurgitation. *JACC Cardiovascular interventions*.
358 2020;13(20):2385-2387.
- 359 11. Tamargo M, Obokata M, Reddy YNV, et al. Functional mitral regurgitation and left
360 atrial myopathy in heart failure with preserved ejection fraction. *European journal of*
361 *heart failure*. 2020;22(3):489-498.
- 362 12. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the
363 Management of Patients With Valvular Heart Disease: A Report of the American
364 College of Cardiology/American Heart Association Joint Committee on Clinical
365 Practice Guidelines. *Journal of the American College of Cardiology*. 2021;77(4):e25-
366 e197.
- 367 13. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the
368 management of valvular heart disease. *European heart journal*. 2022;43(7):561-632.
- 369 14. Deferm S, Bertrand PB, Verbrugge FH, et al. Atrial Functional Mitral Regurgitation:
370 JACC Review Topic of the Week. *Journal of the American College of Cardiology*.
371 2019;73(19):2465-2476.
- 372 15. Chen YC, Voskoboinik A, Gerche A, Marwick TH, McMullen JR. Prevention of
373 Pathological Atrial Remodeling and Atrial Fibrillation: JACC State-of-the-Art
374 Review. *Journal of the American College of Cardiology*. 2021;77(22):2846-2864.

- 375 16. Thomas L, Abhayaratna WP. Left Atrial Reverse Remodeling: Mechanisms,
376 Evaluation, and Clinical Significance. *JACC Cardiovascular imaging*. 2017;10(1):65-
377 77.
- 378 17. Soulat-Dufour L, Lang S, Addetia K, et al. Restoring Sinus Rhythm Reverses
379 Cardiac Remodeling and Reduces Valvular Regurgitation in Patients With Atrial
380 Fibrillation. *Journal of the American College of Cardiology*. 2022;79(10):951-961.
- 381 18. Ganesan AN, Shipp NJ, Brooks AG, et al. Long-term outcomes of catheter ablation of
382 atrial fibrillation: a systematic review and meta-analysis. *Journal of the American*
383 *Heart Association*. 2013;2(2):e004549.
- 384 19. Kisheva A, Yotov Y. Risk factors for recurrence of atrial fibrillation. *Anatolian*
385 *journal of cardiology*. 2021;25(5):338-345.
- 386 20. Castellá M, Kotecha D, van Laar C, et al. Thoracoscopic vs. catheter ablation for
387 atrial fibrillation: long-term follow-up of the FAST randomized trial. *Europace* :
388 *European pacing, arrhythmias, and cardiac electrophysiology : journal of the*
389 *working groups on cardiac pacing, arrhythmias, and cardiac cellular*
390 *electrophysiology of the European Society of Cardiology*. 2019;21(5):746-753.
- 391 21. Ma N, Ding S, Zeng L, et al. Immediate electrophysiological characteristics following
392 modified thoracoscopic ablation via unilateral approach for non-valvular atrial
393 fibrillation. *Heart and vessels*. 2021;36(6):874-881.
- 394 22. Thomas JD, Raissi SR. Atrial Fibrillation Begets Mitral Regurgitation, or Is it Vice
395 Versa? *JACC Cardiovascular imaging*. 2019;12(4):678-680.
- 396 23. Silbiger JJ. Does left atrial enlargement contribute to mitral leaflet tethering in
397 patients with functional mitral regurgitation? Proposed role of atrigenic leaflet
398 tethering. *Echocardiography (Mount Kisco, NY)*. 2014;31(10):1310-1311.
- 399 24. Kihara T, Gillinov AM, Takasaki K, et al. Mitral regurgitation associated with mitral
400 annular dilation in patients with lone atrial fibrillation: an echocardiographic study.
401 *Echocardiography (Mount Kisco, NY)*. 2009;26(8):885-889.
- 402 25. Nishino S, Watanabe N, Ashikaga K, et al. Reverse Remodeling of the Mitral Valve
403 Complex After Radiofrequency Catheter Ablation for Atrial Fibrillation: A Serial 3-
404 Dimensional Echocardiographic Study. *Circulation Cardiovascular imaging*.
405 2019;12(10):e009317.
- 406 26. Luo Y, Zhu Y, Guan X, Lin Y. Assessment of mitral annulus and mitral leaflet in
407 nonvalvular atrial fibrillation patients with various degrees of mitral regurgitation:
408 Real time 3D transesophageal echocardiography. *Echocardiography (Mount Kisco,*
409 *NY)*. 2018;35(4):481-486.
- 410 27. Debonnaire P, Al Amri I, Leong DP, et al. Leaflet remodelling in functional mitral
411 valve regurgitation: characteristics, determinants, and relation to regurgitation
412 severity. *European heart journal Cardiovascular Imaging*. 2015;16(3):290-299.
- 413 28. Wei K, Bao C, Zhao D, Zhang J, Mei J, Ma N. Effectiveness of Maze IV procedure
414 versus thoracoscopic ablation for atrial fibrillation: a propensity score-matched
415 analysis. *Annals of cardiothoracic surgery*. 2024;13(2):165-172.
- 416 29. Nakamura K, Takagi T, Kogame N, et al. Impact of atrial mitral and tricuspid
417 regurgitation on atrial fibrillation recurrence after ablation. *Journal of*
418 *electrocardiology*. 2021;66:114-121.

419

420

421 **Figure legend**

422 Figure 1 Six-year Kaplan-Meier curve for freedom from AF recurrence and comparison of
423 mitral regurgitation reduction between SR and non-SR patients.

424 Figure 1A. Six-year Kaplan-Meier curve for atrial fibrillation (AF) patients with moderate
425 atrial functional mitral regurgitation (AFMR) freedom from AF recurrence. 1B Sinus rhythm
426 (SR) maintenance of AF patients with moderate AFMR benefits mitral regurgitation
427 reduction ($P<0.0001$) compared to the non-SR patients.

428

429 Figure 2 Comparison of left atrial diameters between SR patients and non-SR patients and the
430 changes in the degree of mitral regurgitation following thoracoscopic AF procedure.

431 Figure 2A. Comparison of left atrial diameters between sinus rhythm (SR) patients and non-
432 SR patients with moderate atrial functional mitral regurgitation (AFMR) and atrial fibrillation
433 (AF) at different time points (pre-procedure, post-procedure, and at the last follow-up).

434 At the last follow-up, the left atrial diameter was 45.04 ± 3.48 mm in SR patients vs.
435 49.60 ± 4.81 mm in non-SR patients ($P=0.004$), a statistically significant difference. 2B. The
436 corresponding changes in the degree of mitral regurgitation in SR and non-SR patients with
437 moderate AFMR and AF.

438 Figure 3 Kaplan-Meier (KM) curves of SR maintenance rate and the changes in the degree of
439 mitral regurgitation following mitral valvuloplasty plus the Cox Maze IV procedure

440 Figure 3A. KM curves of sinus rhythm (SR) maintenance rate for severe atrial functional
441 mitral regurgitation patients with atrial fibrillation (AF) and severe primary mitral
442 regurgitation patients with AF. The KM curves showed no statistical difference between the
443 two groups following Cox Maze IV procedure. 3B. the degree of mitral regurgitation in atrial

444 fibrillation (AF) patients with severe atrial functional mitral regurgitation and those with
445 severe primary mitral regurgitation before the procedure.^{3C} the degree of mitral regurgitation
446 in AF patients with severe atrial functional mitral regurgitation and those with severe primary
447 mitral regurgitation after the procedure.

448

449

450

451

452

453

454

455

456

457

458

459

460

461 **Table 1 Patient Characteristics of three groups. Patients with moderate atrial functional mitral**
 462 **regurgitation (AFMR) and atrial fibrillation (AF) (MAR group). Patients with severe AFMR**
 463 **and AF (SAR group). Patients with severe primary mitral regurgitation and AF (SPR group).**

Characteristics	MAR(n=33)	SAR (n = 56)	SPR (n = 56)	P-Value(SAR/SPR)	SMD
Age, year, mean ± SD	70.27±6.46	70.54±5.91	66.43±6.39	0.001	0.667
Male (%)	20 (60.61)	37 (66.1)	36 (64.3)	>0.999	0.037
Hypertension (%)	19 (57.58)	42 (75.0)	27 (48.2)	0.007	0.573
Diabetes (%)	10 (30.30)	15 (26.8)	9 (16.1)	0.25	0.263
Previous cerebrovascular accident (%)	3 (9.09)	7 (12.5)	4 (7.1)	0.525	0.181
Coronary artery disease (%)	8 (24.24)	15 (26.8)	6 (10.7)	0.053	0.421
NYHA class III-IV (%)	15 (45.45)	34 (60.7)	38 (67.9)	0.554	0.149
CHA2DS2-VASC Score (median [IQR])	3.00 [3.00,4.00]	3.00 [3.00, 4.00]	2.00 [2.00, 3.00]	0.001	0.647
Duration of AF (median [IQR])	72.00 [48.00,108.00]	66.00 [36.00, 96.00]	60.00 [24.00, 72.00]	0.02	0.465

464

465

466

467

468

469

470

471

472

473

474

475

476

477 **Table 2 Postoperative complications of patients with severe atrial functional mitral**
478 **regurgitation and atrial fibrillation (AF) (SAR group) and patients with severe primary mitral**
479 **regurgitation and AF (SPR group).**

Postoperative Event	SAR (n = 56)	SPR (n = 56)	P.value
Stroke	2	0	0.495
Pneumonia	6	3	0.489
Poor wound healing	1	0	>0.999
Prolonged ventilation	7	4	0.527
Acute renal failure	4	1	0.364
Blood product transfusion	7	2	0.162
Reoperation for bleeding	1	0	>0.999
New pacemaker	3	1	0.618
Mortality within 30 days	2	0	0.495
Stays, day (median [IQR])	10.00 [9.00, 12.75]	7.00 [7.00, 8.25]	<0.001

480

481

482

483

484

485

486

487

488

489

490

491

492

493



494

495 **Table 3 Comparison of cardiac remodeling between patients with severe atrial functional mitral**
 496 **regurgitation and atrial fibrillation (AF) (SAR group) and patients with severe primary mitral**
 497 **regurgitation and AF (SPR group).**


Characteristics	SAR (n = 54)	SPR (n = 56)	P-Value	SMD
preLAD, mm, mean ± SD	54.61±5.57	53.95±5.22	0.519	0.123
preLVEDD, mm, mean ± SD	50.61±3.85	56.30±5.84	<0.001	1.150
preLVEF (%), mean ± SD	55.65±3.77	51.48±4.85	<0.001	0.960
postLAD, mm, mean ± SD	48.31±2.60	46.45±3.07	0.001	0.656
postLVEDD, mm, mean ± SD	49.41±2.93	50.64±4.18	0.077	0.342
postLVEF (%), mean ± SD	54.87±5.46	49.25±5.87	<0.001	0.992
fLAD, mm, mean ± SD	48.46±3.80	46.02±2.94	<0.001	0.720
fLVEDD, mm, mean ± SD	51.52±3.54	52.29±3.61	0.263	0.214
fLVEF (%), mean ± SD	54.80±4.93	51.27±5.94	0.001	0.646

498 preLAD, pre-operative left atrial diameter; preLVEDD, pre-operative left ventricular end-diastolic
 499 diameter; preLVEF, pre-operative left ventricular ejection fraction; postLAD, post-operative left atrial
 500 diameter; postLVEDD, post-operative left ventricular end-diastolic diameter; preLVEF, post-
 501 operative left ventricular ejection fraction; fLAD, follow-up left atrial diameter; fLVEDD, follow-up
 502 left ventricular end-diastolic diameter; fLVEF, follow-up left ventricular ejection fraction

503



A



B

